Intra-Cellular Therapies, Inc.
430 East 29th Street, Suite 900
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor, is being developed for the treatment of CNS and non-CNS indications.
1 job with Intra-Cellular Therapies, Inc.
Candidates should possess a minimum of a BA/BS degree with 2 years of experience in organic chemistry, process chemistry, or related disciplines.